USA remote
Study Manager, Toxicology
About this role
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.
Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients. The Opportunity: The preclinical study manager is responsible for the operational activities associated with performing non-GLP and GLP toxicology studies from research to late phases of clinical development. This includes being the primary operational contact and representative for RevMed to the contract research organization (CRO) performing each study.
He/she will be responsible for ensuring that each study’s scientific and corporate objectives are achieved, and are compliant with appropriate regulations, policies, standard operating procedures, and all relevant international regulatory guidelines/regulations. Timely resolution of study-related issues, liaising with internal experts and/or consultants, and informing appropriate personnel are pivotal to being successful in this role.
Required Skills, Experience and Education: Work with Contract Research Organizations (CROs), internal subject matter experts, and toxicologists to help design protocols that achieve the scientific objectives of each study. Monitor non-GLP and GLP toxicology studies through effectively managing day-to-day study-related activities and ensure study objectives are met against project goals. Assist toxicologists in the review of protocols, study reports, and protocol/report amendments to ensure high-quality results are generated by CROs.